BACKGROUND: Secondary stroke prevention guidelines recommend antithrombotic agents such as over-the-counter aspirin, prescription antiplatelet agents, or anticoagulant agents. PURPOSE: The study was designed to measure whether use of outpatient antithrombotic agents is increasing among stroke survivors. METHODS: The sample consisted of 4168 people who self-reported cerebrovascular disease and who participated in the Medical Expenditure Panel Survey, an annual representative sample of the U.S., during the years 2000-2006. Use of antithrombotic agents was calculated from face-to-face interviews about the use of aspirin and from pharmacies about the use of prescription medications. Cochran-Armitage tests were used to detect temporal trends and multivariate models to identify predictors of use of antithrombotic agents. RESULTS: Pooling results across the 7 years, it was found that 57% were taking aspirin, 66% were using any antiplatelet agent, and 75% were using any antithrombotic agent. After excluding people who said aspirin was unsafe, 81% were using any antithrombotic agent. During the study period, use of prescription antiplatelet agents increased (p<0.001) but there was no temporal change in use of antithrombotic agents overall. In multivariate models, being aged >65 years, male gender, non-Hispanic ethnicity, having a usual source of care, and poor or fair health status were associated with use of an antithrombotic agent (p<0.05). CONCLUSIONS: Although a high percentage of stroke survivors appear to use an antithrombotic agent, further research should investigate whether and how to improve care among the remaining 20% of stroke survivors, particularly among younger, female, and Hispanic patients. 2010 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
BACKGROUND: Secondary stroke prevention guidelines recommend antithrombotic agents such as over-the-counter aspirin, prescription antiplatelet agents, or anticoagulant agents. PURPOSE: The study was designed to measure whether use of outpatient antithrombotic agents is increasing among stroke survivors. METHODS: The sample consisted of 4168 people who self-reported cerebrovascular disease and who participated in the Medical Expenditure Panel Survey, an annual representative sample of the U.S., during the years 2000-2006. Use of antithrombotic agents was calculated from face-to-face interviews about the use of aspirin and from pharmacies about the use of prescription medications. Cochran-Armitage tests were used to detect temporal trends and multivariate models to identify predictors of use of antithrombotic agents. RESULTS: Pooling results across the 7 years, it was found that 57% were taking aspirin, 66% were using any antiplatelet agent, and 75% were using any antithrombotic agent. After excluding people who said aspirin was unsafe, 81% were using any antithrombotic agent. During the study period, use of prescription antiplatelet agents increased (p<0.001) but there was no temporal change in use of antithrombotic agents overall. In multivariate models, being aged >65 years, male gender, non-Hispanic ethnicity, having a usual source of care, and poor or fair health status were associated with use of an antithrombotic agent (p<0.05). CONCLUSIONS: Although a high percentage of stroke survivors appear to use an antithrombotic agent, further research should investigate whether and how to improve care among the remaining 20% of stroke survivors, particularly among younger, female, and Hispanic patients. 2010 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
Authors: Yuji Okura; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Richard J Rodeheffer Journal: J Clin Epidemiol Date: 2004-10 Impact factor: 6.437
Authors: P A Wolf; G P Clagett; J D Easton; L B Goldstein; P B Gorelick; M Kelly-Hayes; R L Sacco; J P Whisnant Journal: Stroke Date: 1999-09 Impact factor: 7.914
Authors: Michael Pignone; George K Anderson; Katherine Binns; Hugh H Tilson; Steven M Weisman Journal: Am J Prev Med Date: 2007-05 Impact factor: 5.043
Authors: E Shahar; A R Folsom; F J Romm; K M Bisgard; P A Metcalf; L Crum; P G McGovern; R G Hutchinson; G Heiss Journal: Am Heart J Date: 1996-05 Impact factor: 4.749
Authors: Janet K Freburger; George M Holmes; Li-Jung E Ku; Malcolm P Cutchin; Kendra Heatwole-Shank; Lloyd J Edwards Journal: Arch Phys Med Rehabil Date: 2011-08 Impact factor: 3.966